SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–April 22, 2022–
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the awarding of incentive awards to Brian Robinson, its new Senior Vice President, Global Medical Affairs.
The Compensation Committee of the Atara Board of Directors granted Mr. Robinson 73,449 shares of Atara common stock, fixed-term stock options to purchase 138,067 shares of Atara common stock and stock options. performance-based stock purchase to purchase 15,689 shares of Atara common stock under the Atara Biotherapeutics, Inc. 2018 Incentive Plan, with an award date of April 18, 2022, as Incentive material for new employee joining Atara, in accordance with Nasdaq listing rule 5635(c)(4).
Restricted share units vest over four years, with 25% vesting on the first quarterly vesting date after the first anniversary of the vesting start date and the remainder vesting in 12 quarterly installments approximately equal to the for the next three years, provided that Mr. Robinson is continuously employed by Atara from such vesting dates. Fixed-term stock options vest over four years, with 25% vesting on the first anniversary of the vesting start date and the remainder vesting in 36 equal monthly installments over the following three years , provided that Mr. Robinson is continuously employed by Atara as of such vesting dates. Performance-based stock options vest upon the achievement of certain performance objectives set by the Atara Board of Directors or the Compensation Committee of the Atara Board of Directors, subject to Mr. Robinson being continuously employed by Atara on the applicable vesting date. The stock options have a term of ten years and an exercise price of $7.73 per share, equal to the closing price per share of Atara common stock as reported by Nasdaq on April 18, 2022.
Atara provides this information pursuant to Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematological cancers and autoimmune diseases . With our flagship program in Phase 3 clinical development and currently under review to support registration in Europe, Atara is the most advanced allogeneic T cell immunotherapy company and intends to rapidly deliver ready treatments employment to patients with unmet medical needs. Our platform exploits the unique biology of EBV T cells and has the ability to treat a wide range of EBV-associated diseases, or other serious illnesses through the incorporation of CARs (chimeric antigen receptors) or TCRs (T cell receptors) altered. Atara applies this unique platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel ® (tabelecleucel) in phase 3 development for post-transplantation lymphoproliferative disease induced by Epstein-Barr virus (EBV + PTLD); ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor (CAR-T) T-cell immunotherapies for solid tumors and hematological malignancies. Improving the lives of patients is our mission and we will never stop working to bring transformative therapies to those in need. Atara is headquartered in South San Francisco and our state-of-the-art research, development and manufacturing facilities are based in Thousand Oaks, California. For more company information, please visit atarabio.com and follow us on Twitter and LinkedIn.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220421006031/en/
CONTACT: INVESTORS & MEDIA:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH OTHER HEALTH
SOURCE: Atara Biotherapeutics, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 04/22/2022 16:01 / DISK: 04/22/2022 16:02
Copyright BusinessWire 2022.